Hot on heels of a positive PhIII, Ablynx files $150M IPO; Shire sues Allergan over dry eye drug rivalry
→ After watching its European share price surge {$ABLX BB} yesterday on positive Phase III data, Ablynx feels it’s perfect timing for an IPO …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
